Lawton J O, Giles G R, Hall J, MacAdam A, Hall R, Matheson T, Bird G
Cancer Treat Rep. 1981 Jan-Feb;65(1-2):13-15.
In 39 patients with advanced colorectal cancer and no previous chemotherapy, treatment with chlorozotocin was associated with a 5% objective response rate and a median survival of 19 weeks. All of the responses occurred in patients with rectal tumors. Mild gastrointestinal symptoms affected 64% of the patients after treatment, but bone marrow suppression was not evident. Chlorozotocin is not effective against colorectal cancer when used as a single agent given as an iv bolus at doses of 120 mg/m2 (30 patients) and 150 mg/m2 (nine patients). However, further studies using a higher dose might be worthwhile.
在39例先前未接受过化疗的晚期结直肠癌患者中，使用氯脲霉素治疗的客观缓解率为5%，中位生存期为19周。所有缓解均发生在直肠肿瘤患者中。治疗后64%的患者出现轻度胃肠道症状，但未观察到明显的骨髓抑制。当以120mg/m²（30例患者）和150mg/m²（9例患者）的剂量静脉推注单药使用时，氯脲霉素对结直肠癌无效。然而，使用更高剂量进行进一步研究可能是值得的。
